Revelation Share Price
NASDAQ: REVB | HealthcareRevelation Stock Performance
Revelation Share Price Chart
Revelation Quarterly Profit & Loss
All figures in USD
Revelation Annual Profit & Loss
All figures in USD
Revelation Balance Sheet
All figures in USD Million
Revelation Cash Flow
All figures in USD Million
Corporate Actions
About Revelation
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
Revelation Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $3.90 | $3.96 | -1.00% |
Oct 2026 | $0.77 | $4.00 | +387.80% |
Sep 2026 | $0.98 | $0.82 | -20.39% |
Aug 2026 | $1.01 | $1.03 | +8.42% |
Jul 2026 | $1.04 | $0.95 | -7.77% |
Jun 2026 | $1.06 | $1.03 | -6.36% |
May 2026 | $1.05 | $1.10 | -4.35% |
Apr 2026 | $1.21 | $1.15 | -6.50% |
Mar 2026 | $1.30 | $1.23 | -6.82% |
Feb 2026 | $1.89 | $1.32 | -34.16% |
Jan 2026 | $0.81 | $2.00 | +152.20% |
Dec 2025 | $0.98 | $0.80 | -17.70% |